AG-ONDANSETRON TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ONDANSETRON (ONDANSETRON HYDROCHLORIDE)

Pieejams no:

ANGITA PHARMA INC.

ATĶ kods:

A04AA01

SNN (starptautisko nepatentēto nosaukumu):

ONDANSETRON

Deva:

8MG

Zāļu forma:

TABLET

Kompozīcija:

ONDANSETRON (ONDANSETRON HYDROCHLORIDE) 8MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

10/30/100

Receptes veids:

Prescription

Ārstniecības joma:

5-HT3 RECEPTOR ANTAGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0131120001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2011-08-22

Produkta apraksts

_ _
_AG-Ondansetron Product Monograph _
_Page 1 of 35 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AG-ONDANSETRON
Ondansetron Tablets
Tablets, 4 mg and 8 mg ondansetron (as ondansetron hydrochloride),
oral
USP
Antiemetic
5-HT3 receptor antagonist
ATC code A04AA01
Angita Pharma Inc.
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
August 22, 2011
Date of Revision:
NOV 16, 2022
Submission Control Number: 268929 _ _
_ _
_AG-Ondansetron Product Monograph _
_Page 2 of 35 _
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
11/2022
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose
and Dosage Adjustment
11/2022
7 WARNINGS AND PRECAUTIONS, Cardiovascular,
Myocardial Ischemia and Coronary Artery Spasm
11/2022
7 WARNINGS AND PRECAUTIONS, Special Populations,
7.1.1 Pregnant Women
10/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics (<18 years of age)
....................................................................................
4
1.2
Geriatrics (≥65 years of age)
....................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and